Johnson & Johnson is moving forward with a vaccine candidate for COVID-19, with human testing starting during September and the first batches available under potential emergency use authorization expected in the first part of 2021.

Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints.

New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure worsening or cardiovascular death compared to placebo, in patients with heart failure with reduced ejection fraction, irrespective of their background therapy.

A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.

One of the key takeaways from BIO-Europe Spring 2020, which was held virtually March 23-27, was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public. 

As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.

A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.

A day after the announcement that remdesivir received Orphan Drug designation for the treatment of COVID-19 from the U.S. Food and Drug Administration, Gilead Sciences submitted a request for the regulatory agency to rescind that offer after an outcry was raised over the potential for exclusivity for the experimental pandemic treatment.

While COVID-19 dominates headlines as the virus has spread across the globe and the pharmaceutical industry has marshaled its forces to develop therapies and diagnostics against the disease, BioSpace takes a look at key industry news not related to the coronavirus.